Idea or Concept – Page 18 – Talk Bio

Actionable Insights Powered by AI

Candel Therapeutics Sees Dramatic Stock Surge Following Successful Phase III Prostate Cancer Trial

9 months ago talkbio0Tagged Approved, CAN-2409, Candel, Malignant neoplasm of prostate, Phase 3 Clinical Trials, surge, United States Food and Drug Administration, viral immunotherapy

Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval

Q32 Bio Inc. Faces Market Volatility After Bempikibart Program Update

9 months ago talkbio0Tagged Autoimmune Diseases, bempikibart, Bio Inc., IL-7/TSLP pathways, Market, Performance, Volatility

Q32 Bio Inc., bempikibart, autoimmune diseases, IL-7/TSLP pathways, stock performance, market volatility

Eli Lilly Announces $15 Billion Share Buyback Plan and 15% Dividend Increase

9 months ago talkbio0Tagged dividend, Drug Industry, Eli, Eli Lilly, Increase, Market, Share Buyback

Eli Lilly, Share Buyback, Dividend Increase, Pharmaceutical Industry, Stock Market

BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets

9 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, crash, liver transaminitis, Obesity, Phase 2 Clinical Trials, Safety

BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash

Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch

9 months ago talkbio0Tagged cancer medicine, Cyclacel, development aspects, Financial cost, Financial Stress, Nasdaq, Risk, strategic alternatives

Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development

Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns

9 months ago talkbio0Tagged Acquisitions, Administration occupational activities, Biopharma, Independence, Inflation, mergers, Policy, Transplant Registry Unified Management Program, United States Food and Drug Administration, Vaccines

Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act

Pragmatic Clinical Trials: Bridging the Gap Between Research and Real-World Practice

9 months ago talkbio0Tagged Clinical Trial Design, Effectiveness, Evidence, Healthcare decision making, Pragmatic Clinical Trials as Topic, Real-world, research

1. Pragmatic Clinical Trials, 2. Real-World Evidence, 3. Clinical Trial Design, 4. Effectiveness Research, 5. Healthcare Decision Making

CDC Faces Uncertainty Amid Leadership Change and Funding Threats

10 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), Dr. Mandy, Funding, health threats, Leadership Change, public health medicine (field), threat

CDC, leadership change, funding threats, public health, emerging health threats, Dave Weldon, Dr. Mandy Cohen

Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy

10 months ago talkbio0Tagged AMD, Attitude, Clinical Trials, Failure (biologic function), File (record), Glycogen storage disease type II, OTLK, Prices, United States Food and Drug Administration

Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing

Biohaven’s Taldefgrobep Alfa Misses Primary Endpoint in Phase 3 SMA Trial, Eyes FDA Discussions and Obesity Indication

10 months ago talkbio0Tagged Discussion (procedure), Indication of (contextual qualifier), Obesity, Phase 3 trial, Spinal Muscular Atrophy, Talditercept alfa, United States Food and Drug Administration

Biohaven, Taldefgrobep Alfa, Spinal Muscular Atrophy (SMA), Phase 3 Trial, FDA Discussions, Obesity Indication